Severe Combined Immunodeficiency Disorders

Immunology and Allergy Clinics of North America

Volumn 35, Issue 4, 2015, Pages 671-694

  Chinn, Ivan K ^a   Shearer, William T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

DiGeorge anomaly; Gene therapy; Newborn screening; Severe combined immunodeficiency disease; Transplantation

Indexed keywords

ALLOTRANSPLANTATION; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CAUSAL ATTRIBUTION; CLINICAL EVALUATION; CONGENITAL ATHYMIA; CONGENITAL DISORDER; DIGEORGE SYNDROME; GENE THERAPY; GENETIC ASSOCIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MANAGED CARE; MEDICAL HISTORY; NATURAL KILLER CELL; NEWBORN SCREENING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; THYMUS TRANSPLANTATION; TREATMENT OUTCOME; DIFFERENTIAL DIAGNOSIS; DISEASE MANAGEMENT; NEWBORN;

DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 84943738290     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2015.07.002     Document Type: Review

References (164)

1. Griffith L.M., Cowan M.J., Notarangelo L.D., et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol 2009, 124:1152-1160.e12.
2. Shearer W.T., Dunn E., Notarangelo L.D., et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 2014, 133:1092-1098.
3. Noguchi M., Yi H., Rosenblatt H.M., et al. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73:147-157.
4. Puck J.M., Deschenes S.M., Porter J.C., et al. The interleukin-2 receptor γ chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet 1993, 2:1099-1104.
5. Al-Herz W., Bousfiha A., Casanova J.-L., et al. Primary immunodeficiency diseases: an update on the classification from the International Union Of Immunological Societies Expert Committee for primary immunodeficiency. Front Immunol 2014, 5:162.
6. Nijman I.J., van Montfrans J.M., Hoogstraat M., et al. Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies. J Allergy Clin Immunol 2014, 133:529-534.e1.
7. Kohn L.A., Seet C.S., Scholes J., et al. Human lymphoid development in the absence of common γ-chain receptor signaling. J Immunol 2014, 192(11):5050-5058.
8. Kovanen P.E., Leonard W.J. Cytokines and immunodeficiency diseases: critical roles of the γc-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev 2004, 202:67-83.
9. Roifman C.M., Zhang J., Chitayat D., et al. A partial deficiency of interleukin-7Rα is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood 2000, 96:2803-2807.
10. Vosshenrich C.A.J., Ranson T., Samson S.I., et al. Roles for common cytokine receptor γ-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK Cells in vivo. J Immunol 2005, 174:1213-1221.
11. Meazza R., Azzarone B., Orengo A.M., et al. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol 2011, 2011:861920.
12. White H., Thrasher A., Veys P., et al. Intrinsic defects of B cell function in X-linked severe combined immunodeficiency. Eur J Immunol 2000, 30:732-737.
13. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004, 22:625-655.
14. Cacalano N.A., Migone T.S., Bazan F., et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J 1999, 18:1549-1558.
15. Macchi P., Villa A., Giliani S., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65-68.
16. Li L., Moshous D., Zhou Y., et al. A founder mutation in artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol 2002, 168:6323-6329.
17. Moshous D., Callebaut I., de Chasseval R., et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001, 105:177-186.
18. Nicolas N., Moshous D., Cavazzana-Calvo M., et al. A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J Exp Med 1998, 188:627-634.
19. van der Burg M., Ijspeert H., Verkaik N.S., et al. A DNA-PKcs mutation in a radiosensitive T(-)B(-) SCID patient inhibits Artemis activation and nonhomologous end-joining. J Clin Invest 2009, 119:91-98.
20. van der Burg M., van Veelen L.R., Verkaik N.S., et al. A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation. J Clin Invest 2006, 116:137-145.
21. Enders A., Fisch P., Schwarz K., et al. A severe form of human combined immunodeficiency due to mutations in DNA Ligase IV. J Immunol 2006, 176:5060-5068.
22. Buck D., Moshous D., de Chasseval R., et al. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol 2006, 36:224-235.
23. Buck D., Malivert L., de Chasseval R., et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 2006, 124:287-299.
24. Puel A., Ziegler S.F., Buckley R.H., et al. Defective IL7R expression in T-B+NK+ severe combined immunodeficiency. Nat Genet 1998, 20:394-397.
25. Siegers G.M., Swamy M., Fernández-Malavé E., et al. Different composition of the human and the mouse γδ T cell receptor explains different phenotypes of CD3γ and CD3δ immunodeficiencies. J Exp Med 2007, 204:2537-2544.
26. de Saint Basile G., Geissmann F., Flori E., et al. Severe combined immunodeficiency caused by deficiency in either the δ or the ε subunit of CD3. J Clin Invest 2004, 114:1512-1517.
27. Dadi H.K., Simon A.J., Roifman C.M. Effect of CD3δ deficiency on maturation of α/β and γ/δ T-cell lineages in severe combined immunodeficiency. N Engl J Med 2003, 349:1821-1828.
28. Gil J., Busto E.M., Garcillán B., et al. A leaky mutation in CD3D differentially affects αβ and γδ T cells and leads to a Tαβ(-)Tγδ(+)B(+)NK(+) human SCID. J Clin Invest 2011, 121:3872-3876.
29. Rieux-Laucat F., Hivroz C., Lim A., et al. Inherited and somatic CD3ζ mutations in a patient with T-cell deficiency. N Engl J Med 2006, 354:1913-1921.
30. Roberts J.L., Lauritsen J.P.H., Cooney M., et al. T(-)B(+)NK(+) severe combined immunodeficiency caused by complete deficiency of the CD3ζ subunit of the T-cell antigen receptor complex. Blood 2007, 109:3198-3206.
31. Arnaiz-Villena A., Timon M., Rodriguez-Gallego C., et al. T lymphocyte signalling defects and immunodeficiency due to the lack of CD3 gamma. Immunodeficiency 1993, 4:121-129.
32. Arnaiz-Villena A., Timon M., Corell A., et al. Primary immunodeficiency caused by mutations in the gene encoding the CD3-γ subunit of the T-lymphocyte receptor. N Engl J Med 1992, 327:529-533.
33. Tchilian E.Z., Wallace D.L., Wells R.S., et al. A deletion in the gene encoding the CD45 antigen in a patient with SCID. J Immunol 2001, 166:1308-1313.
34. Kung C., Pingel J.T., Heikinheimo M., et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med 2000, 6:343-345.
35. Roberts J.L., Buckley R.H., Luo B., et al. CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proc Natl Acad Sci U S A 2012, 109:10456-10461.
36. Shiow L.R., Roadcap D.W., Paris K., et al. The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency. Nat Immunol 2008, 9:1307-1315.
37. Shiow L.R., Paris K., Akana M.C., et al. Severe combined immunodeficiency (SCID) and attention deficit hyperactivity disorder (ADHD) associated with a coronin-1A mutation and a chromosome 16p11.2 deletion. Clin Immunol 2009, 131:24-30.
38. Föger N., Rangell L., Danilenko D.M., et al. Requirement for coronin 1 in T lymphocyte trafficking and cellular homeostasis. Science 2006, 313:839-842.
39. Benke P.J., Dittmar D. Purine dysfunction in cells from patients with adenosine deaminase deficiency. Pediatr Res 1976, 10:642-646.
40. Cohen A., Doyle D., Martin D.W., et al. Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase. N Engl J Med 1976, 295:1449-1454.
41. Kameoka J., Tanaka T., Nojima Y., et al. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993, 261:466-469.
42. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodefic Rev 1991, 3:45-81.
43. Pannicke U., Tuchschmid P., Friedrich W., et al. Two novel missense and frameshift mutations in exons 5 and 6 of the purine nucleoside phosphorylase (PNP) gene in a severe combined immunodeficiency (SCID) patient. Hum Genet 1996, 98:706-709.
44. Lagresle-Peyrou C., Six E.M., Picard C., et al. Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nat Genet 2009, 41:106-111.
45. Pannicke U., Honig M., Hess I., et al. Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nat Genet 2009, 41:101-105.
46. Pai S.-Y., Logan B.R., Griffith L.M., et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 2014, 371:434-446.
47. DiSanto J.P., Rieux-Laucat F., Dautry-Varsat A., et al. Defective human interleukin 2 receptor gamma chain in an atypical X chromosome-linked severe combined immunodeficiency with peripheral T cells. Proc Natl Acad Sci U S A 1994, 91:9466-9470.
48. Schmalstieg F.C., Leonard W.J., Noguchi M., et al. Missense mutation in exon 7 of the common gamma chain gene causes a moderate form of X-linked combined immunodeficiency. J Clin Invest 1995, 95:1169-1173.
49. Wada T., Toma T., Okamoto H., et al. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency. Blood 2005, 106:2099-2101.
50. de Saint-Basile G., Le Deist F., de Villartay J.P., et al. Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). J Clin Invest 1991, 87:1352-1359.
51. Palmer K., Green T.D., Roberts J.L., et al. Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency. J Allergy Clin Immunol 2007, 120:423-428.
52. Omenn G.S. Familial reticuloendotheliosis with eosinophilia. N Engl J Med 1965, 273:427-432.
53. Villa A., Notarangelo L.D., Roifman C.M. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol 2008, 122:1082-1086.
54. Villa A., Santagata S., Bozzi F., et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell 1998, 93:885-896.
55. Gruber T.A., Shah A.J., Hernandez M., et al. Clinical and genetic heterogeneity in Omenn syndrome and severe combined immune deficiency. Pediatr Transplant 2009, 13:244-250.
56. Grunebaum E., Bates A., Roifman C.M. Omenn syndrome is associated with mutations in DNA ligase IV. J Allergy Clin Immunol 2008, 122:1219-1220.
57. Pollack M.S., Kirkpatrick D., Kapoor N., et al. Identification by HLA typing of intrauterine-derived maternal T cells in four patients with severe combined immunodeficiency. N Engl J Med 1982, 307:662-666.
58. Müller S.M., Ege M., Pottharst A., et al. Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients. Blood 2001, 98:1847-1851.
59. Appleton A., Curtis A., Wilkes J., et al. Differentiation of materno-fetal GVHD from Omenn's syndrome in pre-BMT patients with severe combined immunodeficiency. Bone Marrow Transplant 1994, 14:157-159.
60. Buckley R.H. The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol 2012, 129:597-604.
61. Shearer W.T., Fleisher T.A., Buckley R.H., et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 2014, 133:961-966.
62. Dvorak C.C., Cowan M.J. Radiosensitive severe combined immunodeficiency disease. Immunol Allergy Clin North Am 2010, 30:125-142.
63. Horn B., Cowan M.J. Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects. J Allergy Clin Immunol 2013, 131:1306-1311.
64. Schuetz C., Neven B., Dvorak C.C., et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood 2013, 123:281-289.
65. South M.A., Montgomery J.R., Richie E., et al. Four-year study of a boy with combined immune deficiency maintained in strict reverse isolation from birth. IV. Immunologic studies. Pediatr Res 1977, 11:71-78.
66. Shearer W.T., Ritz J., Finegold M.J., et al. Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency. N Engl J Med 1985, 312:1151-1159.
67. Hershfield M. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA). Immunodeficiency 1993, 4:93-97.
68. Gaspar H. Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Immunol Allergy Clin North Am 2010, 30:221-236.
69. Hershfield M. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat 1995, 5:107-112.
70. Malacarne F., Benicchi T., Notarangelo L.D., et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol 2005, 35:3376-3386.
71. Hagin D., Burroughs L., Torgerson T.R. Hematopoietic Stem Cell Transplant for Immune Deficiency and Immune Dysregulation Disorders. Immunol Allergy Clin North Am 2015, in press.
72. Gatti R.A., Meuwissen H.J., Allen H.D., et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 292:1366-1369.
73. Meuwissen H.J., Gatti R.A., Terasaki P.I., et al. Treatment of lymphopenic hypogammaglobulinemia and bone-marrow aplasia by transplantation of allogeneic marrow. N Engl J Med 1969, 281:691-697.
74. Vossen J.M., de Koning J., van Bekkum D.W., et al. Successful treatment of an infant with severe combined immunodeficiency by transplantation of bone marrow cells from an uncle. Clin Exp Immunol 1973, 13:9-20.
75. O'Reilly R.J., Dupont B., Pahwa S., et al. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977, 297:1311-1318.
76. Reisner Y., Kirkpatrick D., Dupont B., et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981, 318:327-331.
77. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983, 61:341-348.
78. Haddad E., Allakhverdi Z., Griffith L.M., et al. Survey on retransplantation criteria for patients with severe combined immunodeficiency. J Allergy Clin Immunol 2014, 133:597-599.
79. Haddad E., Leroy S., Buckley R.H. B-cell reconstitution for SCID: Should a conditioning regimen be used in SCID treatment?. J Allergy Clin Immunol 2013, 131(4):994-1000.
80. Buckley R.H., Win C.M., Moser B.K., et al. Post-Transplantation B Cell Function in Different Molecular Types of SCID. J Clin Immunol 2013, 33(1):96-110.
81. Grunebaum E., Roifman C.M. Bone marrow transplantation using HLA-matched unrelated donors for patients suffering from severe combined immunodeficiency. Hematol Oncol Clin North Am 2011, 25:63-73.
82. Dvorak C.C., Hassan A., Slatter M.A., et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol 2014, 134:935-943.e15.
83. Hassan A., Lee P., Maggina P., et al. Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency. J Allergy Clin Immunol 2014, 133:1660-1666.
84. Keller M.D., Chen D.F., Condron S.A., et al. The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID). J Clin Immunol 2007, 27:109-116.
85. Kamili Q.U.A., Seeborg F.O., Saxena K., et al. Severe cutaneous human papillomavirus infection associated with natural killer cell deficiency following stem cell transplantation for severe combined immunodeficiency. J Allergy Clin Immunol 2014, 134:1451-1453.e1.
86. Laffort C., Deist F.L., Favre M., et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common γc cytokine receptor subunit or JAK-3 deficiency. Lancet 2004, 363:2051-2054.
87. Koppelmans V., Breteler M.M.B., Boogerd W., et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 2012, 30(10):1080-1086.
88. Titman P., Pink E., Skucek E., et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 2008, 112:3907-3913.
89. Rogers M.H., Lwin R., Fairbanks L., et al. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr 2001, 139:44-50.
90. Railey M.D., Lokhnygina Y., Buckley R.H. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr 2009, 155:834-840. e1.
91. Buckley R. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: long-term outcomes. Immunol Res 2011, 49:25-43.
92. Myers L.A., Patel D.D., Puck J.M., et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002, 99:872-878.
93. Onodera M., Ariga T., Kawamura N., et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 1998, 91:30-36.
94. Kohn D.B., Weinberg K.I., Nolta J.A., et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995, 1:1017-1023.
95. Bordignon C., Notarangelo L.D., Nobili N., et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA negative immunodeficient patients. Science 1995, 270:470.
96. Hoogerbrugge P.M., van Beusechem V.W., Fischer A., et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 1996, 3:179-183.
97. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
98. Hacein-Bey-Abina S., Garrigue A., Wang G.P., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
99. Howe S.J., Mansour M.R., Schwarzwaelder K., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008, 118:3143-3150.
100. Cappelli B., Aiuti A. Gene therapy for adenosine deaminase deficiency. Immunol Allergy Clin North Am 2010, 30:249-260.
101. Gaspar H.B., Cooray S., Gilmour K.C., et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011, 3:97ra80.
102. Candotti F., Shaw K.L., Muul L., et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 2012, 120(18):3635-3646.
103. Thrasher A.J., Hacein-Bey-Abina S., Gaspar H.B., et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005, 105:4255-4257.
104. Hacein-Bey-Abina S., Pai S.-Y., Gaspar H.B., et al. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 2014, 371:1407-1417.
105. Naldini L., Blomer U., Gallay P., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263.
106. Zufferey R., Dull T., Mandel R.J., et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998, 72:9873-9880.
107. DiGeorge A.M. Discussion of Cooper MD, Peterson RDA, Good RA. A new concept of cellular basis of immunity. J Pediatr 1965, 67:907.
108. Conley M.E., Beckwith J.B., Mancer J.F.K., et al. The spectrum of the DiGeorge syndrome. J Pediatr 1979, 94:883-890.
109. Barrett D.J., Ammann A.J., Wara D.W., et al. Clinical and immunologic spectrum of the DiGeorge syndrome. J Clin Lab Immunol 1981, 6:1-6.
110. Hong R. The DiGeorge anomaly. Immunodefic Rev 1991, 3:1-14.
111. DiGeorge A.M. Maldescent of the thymus. Pediatr Pathol 1994, 14:178. [author reply: 9-80].
112. Rope A.F., Cragun D.L., Saal H.M., et al. DiGeorge anomaly in the absence of chromosome 22q11.2 deletion. J Pediatr 2009, 155:560-565.e1.
113. Markert M. Thymus transplantation. Stiehm's immune deficiencies 2014, 1059-1067. Academic Press, Waltham (MA). 1st edition. K. Sullivan, E. Stiehm (Eds.).
114. Markert M. Defects in thymic development: DiGeorge/CHARGE/chromosome 22q11.2 deletion. Stiehm's immune deficiencies 2014, 221-242. Academic Press, Waltham (MA). 1st edition. K. Sullivan, E. Stiehm (Eds.).
115. Lingman Framme J., Borte S., von Döbeln U., et al. Retrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome. J Clin Immunol 2014, 34:514-519.
116. Flanagan S.P. 'Nude', a new hairless gene with pleiotropic effects in mouse. Genet Res 1966, 8:295-309.
117. Pantelouris E.M. Absence of thymus in a mouse mutant. Nature 1968, 217:370-371.
118. Nehls M., Pfeifer D., Schorpp M., et al. New member of the winged-helix protein family disrupted in mouse and rat nude mutations. Nature 1994, 372:103-107.
119. Frank J., Pignata C., Panteleyev A.A., et al. Exposing the human nude phenotype. Nature 1999, 398:473-474.
120. Pignata C., Fiore M., Guzzetta V., et al. Congenital alopecia and nail dystrophy associated with severe functional T-cell immunodeficiency in two sibs. Am J Med Genet 1996, 65:167-170.
121. Markert M.L., Hummell D.S., Rosenblatt H.M., et al. Complete DiGeorge syndrome: persistence of profound immunodeficiency. J Pediatr 1998, 132:15-21.
122. Markert M.L., Marques J.G., Neven B., et al. First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases. Blood 2011, 117:688-696.
123. Markert M.L., Alexieff M.J., Li J., et al. Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome. Blood 2004, 104:2574-2581.
124. Markert M.L., Alexieff M.J., Li J., et al. Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol 2004, 113:734-741.
125. Markert M.L., Devlin B.H., Alexieff M.J., et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood 2007, 109:4539-4547.
126. Chinn I.K., Milner J.D., Scheinberg P., et al. Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and FoxP3-T cells in complete DiGeorge anomaly. Clin Exp Immunol 2013, 173:140-149.
127. Markert M.L., Devlin B.H., Chinn I.K., et al. Factors affecting success of thymus transplantation for complete DiGeorge anomaly. Am J Transplant 2008, 8:1729-1736.
128. Chinn I.K., Devlin B.H., Li Y.-J., et al. Long-term tolerance to allogeneic thymus transplants in complete DiGeorge anomaly. Clin Immunol 2008, 126:277-281.
129. Chinn I.K., Olson J.A., Skinner M.A., et al. Mechanisms of tolerance to parental parathyroid tissue when combined with human allogeneic thymus transplantation. J Allergy Clin Immunol 2010, 126:814-820.
130. Zheng P., Norosk L.M., Hanson I.C., et al. Molecular mechanisms of functional natural killer deficiency in patients with partial DiGeorge syndrome. J Allergy Clin Immunol 2015, 135(5):1293-1302.
131. Daguindau N., Decot V., Nzietchueng R., et al. Immune constitution monitoring after PBMC transplantation in complete DiGeorge syndrome: an eight-year follow-up. Clin Immunol 2008, 128:164-171.
132. Land M.H., Garcia-Lloret M.I., Borzy M.S., et al. Long-term results of bone marrow transplantation in complete DiGeorge syndrome. J Allergy Clin Immunol 2007, 120:908-915.
133. Bensoussan D., Le Deist F., Latger-Cannard V., et al. T-cell immune constitution after peripheral blood mononuclear cell transplantation in complete DiGeorge syndrome. Br J Haematol 2002, 117:899-906.
134. Inoue H., Takada H., Kusuda T., et al. Successful cord blood transplantation for a CHARGE syndrome with CHD7 mutation showing DiGeorge sequence including hypoparathyroidism. Eur J Pediatr 2010, 169:839-844.
135. Bowers D.C., Lederman H.M., Sicherer S.H., et al. Immune constitution of complete DiGeorge anomaly by transplantation of unmobilised blood mononuclear cells. Lancet 1998, 352:1983-1984.
136. Janda A., Sedlacek P., Hönig M., et al. Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly. Blood 2010, 116:2229-2236.
137. Mazzolari E., Forino C., Guerci S., et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol 2007, 120:892-899.
138. Markert M.L. Treatment of infants with complete DiGeorge anomaly. J Allergy Clin Immunol 2008, 121:1063.
139. Chan K., Puck J.M. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 2005, 115:391-398.
140. Kubiak C., Jyonouchi S., Kuo C., et al. Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency. J Allergy Clin Immunol 2014, 2:697-702.
141. Modell V., Knaus M., Modell F. An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia. Immunol Res 2014, 60:145-152.
142. Routes J.M., Grossman W.J., Verbsky J., et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA 2009, 302:2465-2470.
143. Kwan A., Abraham R.S., Currier R., et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014, 312:729-738.
144. Heimall J., Keller M., Saltzman R., et al. Diagnosis of 22q11.2 deletion syndrome and artemis deficiency in two children with T-B-NK+ immunodeficiency. J Clin Immunol 2012, 32:1141-1144.
145. Borte S., Wang N., Óskarsdóttir S., et al. Newborn screening for primary immunodeficiencies: beyond SCID and XLA. Ann N Y Acad Sci 2011, 1246:118-130.
146. Turul T., Tezcan I., Artac H., et al. Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency. Eur J Pediatr 2009, 168:87-93.
147. Gadola S.D., Moins-Teisserenc H.T., Trowsdale J., et al. TAP deficiency syndrome. Clin Exp Immunol 2000, 121:173-178.
148. Furukawa H., Murata S., Yabe T., et al. Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest 1999, 103:755-758.
149. Klein C., Lisowska-Grospierre B., LeDeist F., et al. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr 1993, 123:921-928.
150. Steimle V., Otten L.A., Zufferey M., et al. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993, 75:135-146.
151. Nagarajan U.M., Louis-Plence P., DeSandro A., et al. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 1999, 10:153-162.
152. Ouederni M., Vincent Q.B., Frange P., et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood 2011, 118:5108-5118.
153. Masternak K., Barras E., Zufferey M., et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998, 20:273-277.
154. Steimle V., Durand B., Barras E., et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Development 1995, 9:1021-1032.
155. Durand B., Sperisen P., Emery P., et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 1997, 16:1045-1055.
156. Engelhardt K.R., McGhee S., Winkler S., et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009, 124:1289-1302.e4.
157. Zhang Q., Davis J.C., Lamborn I.T., et al. Combined immunodeficiency associated with DOCK8 mutations. New Engl J Med 2009, 361:2046-2055.
158. Hauck F., Randriamampita C., Martin E., et al. Primary T-cell immunodeficiency with immunodysregulation caused by autosomal recessive LCK deficiency. J Allergy Clin Immunol 2012, 130:1144-1152.e11.
159. Goldman F.D., Ballas Z.K., Schutte B.C., et al. Defective expression of p56lck in an infant with severe combined immunodeficiency. J Clin Invest 1998, 102:421-429.
160. Feske S., Picard C., Fischer A. Immunodeficiency due to mutations in ORAI1 and STIM1. Clin Immunol 2010, 135:169-182.
161. Feske S., Gwack Y., Prakriya M., et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006, 441:179-185.
162. Picard C., McCarl C.-A., Papolos A., et al. STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. New Engl J Med 2009, 360:1971-1980.
163. Keller M.D., Ganesh J., Heltzer M., et al. Severe combined immunodeficiency resulting from mutations in MTHFD1. Pediatrics 2013, 131:e629-e634.
164. Borzutzky A., Crompton B., Bergmann A.K., et al. Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter. Clin Immunol 2009, 133:287-294.